Last update Aug. 24, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
B02BD10 is Human von Willebrand factor (vWF) in ATC Code/s.
Is written in other languages:B02BD10 is also known as
B02BD10 belongs to this group or family:
Main tradenames from several countries containing B02BD10 in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 250.000 - 20.000.000 | daltons |
VD | 0.001 | l/Kg |
T½ | 16.5 ± 4.1 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Human von Willebrand factor is a plasma glycoprotein of 2,050 amino acids that acts as a blood coagulation factor. Vonicog alfa is a recombinant form of human von Willebrand factor. It is used to control bleeding episodes in von Willebrand disease and, along with factor VIII, hemophilia A. Intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high molecular weigh and its binding to coagulation factor VIII make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Expert authors consider the use of this medication probably compatible during breastfeeding. (Hale). According to the WHO list of essential drugs, coagulation factors with a similar glycoprotein structure and high molecular weight, such as factor II, VII, VIII, IX and X, are compatible with breastfeeding. (WHO 2002)